Razazan et al. demonstrated that GPR43 inhibition exacerbates Aβ-induced neurotoxicity, whereas its activation attenuates AD-associated pathological changes (Razazan et al. 2021). The gene discussed is FFAR2; the disease is Alzheimer disease.